UBS Group’s Serina Therapeutics SER Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.61K | Buy |
1,347
+1,342
| +26,840% | +$2.52K | ﹤0.01% | 9320 |
|
|
2026
Q1 | $10 | Sell |
5
-428
| -99% | -$942 | ﹤0.01% | 10330 |
|
|
2025
Q4 | $829 | Sell |
433
-3,033
| -88% | -$12.3K | ﹤0.01% | 9799 |
|
|
2025
Q3 | $18.6K | Buy |
3,466
+3,465
| +346,500% | +$18.4K | ﹤0.01% | 8200 |
|
|
2025
Q2 | $6 | Sell |
1
-746
| -100% | -$4.24K | ﹤0.01% | 10172 |
|
|
2025
Q1 | $4.24K | Sell |
747
-3,062
| -80% | -$14.5K | ﹤0.01% | 9131 |
|
|
2024
Q4 | $19.1K | Buy |
3,809
+3,808
| +380,800% | +$22.5K | ﹤0.01% | 7907 |
|
|
2024
Q3 | $7 | Sell |
1
-1,026
| -100% | -$8.14K | ﹤0.01% | 9376 |
|
|
2024
Q2 | $9.84K | Buy |
1,027
+1,022
| +20,440% | +$10.1K | ﹤0.01% | 7724 |
|
|
2024
Q1 | $67 | Sell |
5
-13
| -72% | -$182 | ﹤0.01% | 8891 |
|
|
2023
Q4 | $238 | Buy |
18
+11
| +157% | +$202 | ﹤0.01% | 8784 |
|
|
2023
Q3 | $160 | Sell |
7
-154
| -96% | -$4.07K | ﹤0.01% | 8767 |
|
|
2023
Q2 | $5.06K | Buy |
161
+160
| +16,000% | +$3.42K | ﹤0.01% | 7476 |
|
|
2023
Q1 | $23 | Sell |
1
-383
| -100% | -$8.8K | ﹤0.01% | 9409 |
|
|
2022
Q4 | $7.43K | Buy |
384
+383
| +38,300% | +$8.07K | ﹤0.01% | 8895 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 11032 |
|
|
2022
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 11049 |
|
|
2022
Q1 | $0 | Sell |
1
-446
| -100% | -$12.7K | ﹤0.01% | 11010 |
|
|
2021
Q4 | $17K | Buy |
447
+445
| +22,250% | +$12K | ﹤0.01% | 8087 |
|
|
2021
Q3 | $0 | Buy |
2
+1
| +100% | +$42 | ﹤0.01% | 10170 |
|
|
2021
Q2 | $0 | Sell |
1
-56
| -98% | -$2.81K | ﹤0.01% | 9900 |
|
|
2021
Q1 | $4K | Sell |
57
-136
| -70% | -$9.52K | ﹤0.01% | 8436 |
|
|
2020
Q4 | $10K | Sell |
193
-409
| -68% | -$23.6K | ﹤0.01% | 7508 |
|
|
2020
Q3 | $17K | Buy |
602
+391
| +185% | +$14K | ﹤0.01% | 6454 |
|
|
2020
Q2 | $7K | Sell |
211
-198
| -48% | -$5.83K | ﹤0.01% | 7238 |
|
|
2020
Q1 | $13K | Sell |
409
-505
| -55% | -$23.8K | ﹤0.01% | 6787 |
|
|
2019
Q4 | $59K | Buy |
914
+351
| +62% | +$19K | ﹤0.01% | 6263 |
|
|
2019
Q3 | $39K | Buy |
563
+311
| +123% | +$29.5K | ﹤0.01% | 6334 |
|
|
2019
Q2 | $33K | Buy |
252
+153
| +155% | +$20.7K | ﹤0.01% | 6267 |
|
|
2019
Q1 | $14K | Sell |
99
-20
| -17% | -$2.92K | ﹤0.01% | 6602 |
|
|
2018
Q4 | $12K | Buy |
+119
| New | +$15.1K | ﹤0.01% | 7153 |
|
Other funds holding SER
VCM
VFT
AWE
CIAM
TRCT
PSB
UBS Group's SER Position: Q2 2026 in Review
UBS Group increased its Serina Therapeutics (SER) stake by 26,840% in Q2 2026, buying an estimated $2.52K and bringing the position to 1,347 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #9320.
UBS Group first reported a position in SER in Q4 2018 and has held it in 31 quarters since. The position peaked at $59K in Q4 2019. 21 funds tracked by Wall St. Rank hold SER as of Q2 2026.
- UBS Group held 1,347 shares of Serina Therapeutics worth $2.61K as of Q2 2026.
- UBS Group bought 1,342 Serina Therapeutics shares in Q2 2026, an estimated $2.52K.
- Serina Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9320 holding.
- UBS Group first reported a position in Serina Therapeutics in Q4 2018 and has held it in 31 quarters since.
- UBS Group's Serina Therapeutics position peaked at $59K in Q4 2019.
- 21 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.